SLC5A2 and heart failure: In this context, sodium-glucose cotransporter-2 (SGLT-2) inhibitors, i.e., empagliflozin in the Empagliflozin Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients-Removing Excess Glucose (EMPA-REG OUTCOME) study [8] and canagliflozin in the Canagliflozin Cardiovascular Assessment Study [10], significantly reduced the rates of CVD events, hospitalization for heart failure (HF), CVD, and total mortality, as well as improved kidney function in T2D patients with established CVD.